Combination treatment for low rectal cancer before surgery
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of short-course radiation, internal radiation (brachytherapy), and several drugs to shrink rectal cancer before surgery. The goal is to improve outcomes and potentially avoid more extensive surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old and willing to have treatment before surgery.
- Your tumor must be low in the rectum, within about 2 inches from the anus.
- The cancer must not have spread to other parts of the body.
- You must not have had prior chemotherapy, radiation, or immunotherapy for this cancer.
- Your cancer must be of the 'microsatellite stable' (MSS) type, which is a lab test result.
- You must be in good overall health, with a performance status score of 0 or 1 (meaning you can look after yourself and are fully active).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of short-course radiation, an immunotherapy drug (adebrelimab), and chemotherapy (CAPEOX) before surgery to help preserve the rectum in people with MSS/pMMR ultra-low rectal cancer. The goal is to shrink the tumor enough to avoid removing the rectum.
This trial tests a new combination of standard chemotherapy, immunotherapy (a drug that helps your immune system fight cancer), and a special diet and/or high-dose vitamin C before surgery for rectal cancer. It aims to shrink the tumor and improve surgery outcomes.
This trial tests a combination of radiation, chemotherapy, and immunotherapy drugs before surgery for people with locally advanced rectal cancer. The goal is to shrink the tumor and improve outcomes for patients with higher-risk disease.
This trial tests giving radiation, chemotherapy, and immunotherapy before surgery for rectal cancer that has not spread far. The goal is to see if this combination shrinks the tumor more and improves outcomes before surgery.
This trial tests adding an immunotherapy drug (pucotenlimab) to standard radiation and chemotherapy before surgery for locally advanced rectal cancer. The goal is to see if this combination can shrink the tumor more effectively and improve outcomes.
This trial tests a new combination of chemotherapy, radiation, and immunotherapy given before surgery for low rectal cancer. It aims to see if this approach can shrink tumors and improve outcomes for patients with a specific type of cancer that is microsatellite stable (MSS).
Hear when a new Rectal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.